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Background. Minor Histocompatibility (H) antigen mismatches significantly influence the outcome of HLA-matched allogeneic
stem cell transplantation. The molecular identification of human H antigens is increasing rapidly. In parallel, clinical application
of minor H antigen typing has gained interest. So far, relevant and simple tools to analyze the minor H antigens in a quick and
reliable way are lacking. Methodology and Findings. We developed a uniform PCR with sequence-specific primers (PCR-SSP)
for 10 different autosomal minor H antigens and H-Y. This genomic minor H antigen typing methodology allows easy
incorporation in the routine HLA typing procedures. DNA from previously typed EBV-LCL was used to validate the
methodology. To facilitate easy interpretation for clinical purposes, a minor H database named dbMinor (http://www.lumc.nl/
dbminor) was developed. Input of the minor H antigen typing results subsequently provides all relevant information for a given
patient/donor pair and additional information on the putative graft-versus-host, graft-versus-tumor and host-versus-graft
reactivities. Significance. A simple, uniform and rapid methodology was developed enabling determination of minor H
antigen genotypes of all currently identified minor H antigens. A dbMinor database was developed to interpret the genomic
typing for its potential clinical relevance. The combination of the minor H antigen genomic typing methodology with the
online dbMinor database and applications facilitates the clinical application of minor H antigens anti-tumor targets after stem
cell transplantation.
Citation: Spierings E, Drabbels J, Hendriks M, Pool J, Spruyt-Gerritse M, et al. (2006) A Uniform Genomic Minor Histocompatibility Antigen Typing
Methodology and Database Designed to Facilitate Clinical Applications. PLoS ONE 1(1): e42. doi:10.1371/journal.pone.0000042
INTRODUCTION
Minor Histocompatibility (H) antigens crucially affect the outcome
of HLA-matched allogeneic stem cell transplantation (SCT) [1].
The influence of minor H antigen disparities between HLA
identical SCT donor and recipient on graft-versus-host disease
(GvHD), graft rejection, and on the graft-versus tumor (GvT)
effect has been extensively reported. [2–4]. Recently, a new
feature of minor H antigens was added comprising its potential to
induce and maintain minor H antigen specific T regulator cells
after an HLA identical but minor H antigen mismatched renal
transplant [5]. The number of molecularly identified minor H
antigens has significantly expanded recently, reaching a total of 10
autosomally encoded [6–14] and 10 Y-chromosome encoded
antigens [15–25]. Genomic typing has been developed for some
minor H antigens and implemented into the routine procedures of
molecular HLA typing. The protocols used however vary and
include: allele-specific PCR with sequence specific primers (PCR-
SSP) (HA-1 [26], HA-2 [27], and HA-3 [12]), PCR-RFLP (HA-1
[28], HA-8 [9], and HB-1 [8]), gene specific PCR-SSP (UGT2B17
[11] and H-Y [29]), and the use of fluorogenic 39-minor groove
binding probes (ACC-1 [30]). The heterogeneity of these
techniques as well as the lack of a molecular typing protocol for
some of the molecularly identified minor H antigens prevent their
clinical application. Additionally, the interpretation of minor H
antigen typing data is relatively complex. Typically, a minor H
antigen may differ with respect to tissue distribution and HLA
restriction molecule. Some minor H antigen disparities are
stimulating the beneficial GvT effect while others are involved in
inducing GvHD [31]. Accordingly, pre-transplant information on
minor H antigens may be of benefit to the patient. For example,
typing of broadly expressed minor H antigen identifies those
recipients who are at risk for GvHD. Information on minor H
antigens with tissue distribution restricted to the hematopoietic
system, e.g. HA-1, HA-2, HB-1, ACC-1, ACC-2, UGT2B17,
PANE1, and SP110 [8,10,11,13,14,32], is crucial for their
potential use in the curative effect GvL of SCT. Likewise, minor
H antigens with restricted tissue expression to solid tumors are of
relevance to enhance the GvT effect after SCT [33,34].
Both the expansion of the genomic identification of minor H
antigens and the growing interest in the application of minor H
antigens as therapeutic tools require a simple and uniform allele
specific PCR protocol, an up-to-date database, and tools that
facilitate interpretation of the combined HLA and minor H
antigen typing data. Here we report on the development of
a uniform methodology for genotyping of all currently molecularly
identified minor H antigens. Moreover, a minor H antigen
database has been developed providing immediate information of
the potential clinical relevance of the minor H antigen typing
results for the relevant donor/recipient pair.
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Development of a uniform genomic minor H antigen
typing methodology
In total PCR-SSP for ten autosomally encoded minor H antigens
and one for the Y-chromosome encoded H-Y minor H antigen
were prepared. The design of the allele specific primers for PCR-
SSP (Table 1) was based on the relevant minor H antigen genomic
sequences and data from dbSNP [35]. Since typing for minor H
antigens will generally be performed in HLA tissue typing
laboratories, we developed the minor H antigen PCR protocol
based on the most commonly used HLA typing protocols [36]. To
this end, primers with a Tm of 62uC were designed. Nucleotide
sequences of the primers are listed in Table 1. For HA-1, one 39
nucleotide was removed from the previously published forward
primers [37]. The reported 39 primers for HA-2 [27] were
shortened by 2 nucleotides on the 59 end. The primers that were
earlier described for HA-3 and H-Y matched the proposed
protocol [12,27,29]. The generated primers for the alleles of HA-
1, HA-2, HA-3, HA-8, ACC-2, SP110 and PANE1 specifically
amplified the correct allele (Table 2). To establish specificity of the
primers for the HB-1 and ACC-1 alleles, mismatches to the gene
sequences were introduced in the primer sequences (shaded
nucleotides in Table 1).
Genomic DNA samples
EBV-LCL typed for HA-8, SP110, PANE1, and UGT2B17 were
provided by Dr. E. Warren, Seattle, USA. For ACC-1 and ACC-
2, EBV-LCL from individuals from the CEPH (Centre d’Etude du
Polymorphisme Humain) panel [10]. The CEPH cell lines have
been used earlier by several researchers for identifying novel minor
H antigens [10,38] and are generally available via the Coriell Cell
Repositories (http://www.coriell.org; Coriell Institute for Medical
Research, Camden, NJ). All cell lines were typed earlier by DNA
sequencing, PCR-RFLP, PCR, CTL recognition, or by a combi-
nation of CTL recognition and genomic linkage analysis (Table 2).
DNA of all samples was isolated using the Chemagic automated
magnetic bead technology platform (Chemagen AG, Baesweiler,
Germany) according to the recommendations of the manufacturer.
Genomic PCR
PCR mixes contained 80 ng genomic DNA, 0.25 U Amplitaq
(Perkin-Elmer, Norwalk, CT), 0.01% gelatin, 0.8 mM dNTP,
0.5 mM specific primers, 1.5 mM MgCl2, 50 mM KCl, 10 mM
Tris HCl (pH 8.3), 6% sucrose, and 1 mM cresol red. To increase
the yield of HA-1 and HB-1 products, primer concentrations were
doubled. The PCR program started with 2 minutes at 94uC,
followed by 10 cycles of 10 seconds at 94uC, and 60 seconds at
65uC. Subsequently, 20 cycles were run using the following
conditions: 10 seconds at 94uC, 50 seconds at 61uC, and
30 seconds at 72uC. Samples were analyzed on a 2% agarose
gel. Internal control primers for human platelet antigen (59-
ACCTAGATAGGTGCGAGCTCACC-39 and 59-CAGACT-
GAGCTTCTCCAGCTTGG-39; 0.125 mM each) were used for
the immunogenic alleles, resulting in a product of 439 bp. For the
non-immunogenic alleles, the human growth hormone-2 control
primers 59-CAGTGCCTTCCCAACCATTCCCTTA-39 and 59-
ATCCACTCACGGATTTCTGTTGTGTTTC-39 were used to
Table 1. PCR primers for allelic typing of minor H antigens.
..................................................................................................................................................
minor H antigen allele 59 primer 39 primer length (bp)
HA-1 +/H CTTAAGGAGTGTGTGCTGCA ACTCCTACACATCCCTCAGA 190
2/R CTTAAGGAGTGTGTGTTGCG ACTCCTACACATCCCTCAGA 190
HA-2 +/V ACAGTCTCTGAGTGGCTCAG GCTCCTGGTAGGGGTTCAC 271
2/M ACAGTCTCTGAGTGGCTCAG GCTCCTGGTAGGGGTTCAT 271
HA-3 +/T CTTCAGAGAGACTTGGTCAC GTTCATGAGCCCATGTTCCAT 129
2/M CTTCAGAGAGACTTGGTCAT AGACTCAGCAGGTTTGTTAC 318
HA-8 +/R TGCAGTCAGCAGATCACCG CTTCTGGGCAACAGTTATGGA 187
2/P TGCAGTCAGCAGATCACCC CTTCTGGGCAACAGTTATGGA 187
HB-1 +/H ATTCTTTTCTATAGGTTCTCTGC AGGGCATATGTTCCACTTGCTT 211
2/Y GCCATTCTTTTCTATAGGTTCTTTGT AGGGCATATGTTCCACTTGCTT 214
ACC-1 +/Y CATTGCCTCAACAGCTTCAAG GGTTGTGGTATCTGTAGGGCGT 137
2/C CATTGCCTCAACAGCTTCAAG GGTTGTGGTATCTGTAGGGCGC 137
ACC-2 +/D GATGGAAAAGGAGTTTGAAGGCGA CAGCCTCCGTTTTGCCTTATC 197
2/G GATGGAAAAGGAGTTTGAAGGCGG CAGCCTCCGTTTTGCCTTATC 197
SP110 +/R AATGTGGTTTGAAGACCAAAAGT CTTGTACTCTCATCTTACCTCT 185
2/G AATGTGGTTTGAAGACCAAAAGT CTTGTACTCTCATCTTACCTCC 185
PANE1 +/R AGGCAAGTCCCACACTCG AATGGGGTAAATGACGTGCTG 207
2/Stop CAGGCAAGTCCCACACTCA AATGGGGTAAATGACGTGCTG 207
UGT2B17 + TGTGTTGGGAATATTCTGACTATAA CCCACTTCTTCAGATCATATGCTT 353
--
H-Y (SRY) + TGGCGATTAAGTCAAATTCGC CCCCCTAGTACCCTGACAATGTATT 136
--
Differences between the primer for the immunogenic allele and the non-immunogenic allele are indicated in bold. The specificity of primers for HB-1 and ACC-1 was
increased by introducing mismatches in the primer sequences (shaded nucleotides). Single nucleotide polymorphisms (SNPs) are underlined. All sequences are depicted
from 59 to 39. H-Y PCR-SSP was based upon the SRY gene sequence.
doi:10.1371/journal.pone.0000042.t001
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Minor H Antigen Typing Tools
PLoS ONE | www.plosone.org 2 December 2006 | Issue 1 | e42amplify a product of 504 bp. Internal control primers for
UGT2B17 had the sequence 59-TGCCAAGTGGAGCACC-
CAA-39 and 59-GCATCTTGCTCTGTGCAGAT-39. These
primers yield a 761 bp product derived from the HLA-DR locus.
Minor H antigen database and applications
All currently available information on the molecularly identified
minor H antigens has been imported into the minor H antigen
database (dbMinor: http://www.lumc.nl/dbminor). Data were
retrieved from the relevant literature obtained via PubMed
(http://www.ncbi.nlm.nih.gov/entrez), from abstracts in proceed-
ings, or has been forwarded to us. Polymorphisms that have not
been functionally characterized as encoding T cell epitopes, as well
as minor H antigens that have only been defined at the cellular
level, are not included. A ‘submission’ page has been constructed
for submitting data on minor H antigen identification directly to
the database. Algorithms and queries were developed for searching
the dbMinor, for screening the expression of the immunogenic
minor H antigenic allele(s) in an HLA-typed individual, and for
screening HLA-typed and minor H antigen-typed donor/recipient
pairs for putative immune reactivities in the specified combination.
The dbMinor database and all applications are available via a web-
based interface.
RESULTS
Analysis and validation of the uniform genomic
minor H antigen typing methodology
Allele specific PCR-SSP on genomic DNA was established for all
minor H antigens and their alleles known to date. Figure 1 displays
representative results of the genomic minor H antigen typing by
PCR-SSP of 2 EBV-LCL. Clear bands in the correct positions
indicate the presence of a minor H antigen allele. Internal control
primers demonstrate a band of 439 bp for the immunogenic allele
and 504 bp for the non-immunogenic allele. The presence of
a minor H antigen allele generally results in a weaker control
band. In the absence of the minor H antigen allele, control bands
are clearly visible, thus demonstrating correct amplification
conditions.
Genomic DNA of 22 reference cell lines was used to validate the
newly developed genomic typing method. Table 2 lists the results
and shows full concordance with the minor H antigen typing
reported previously.
Minor H antigen genotyping of the CEPH Panel of
the 13th IHWS
Upon development and validation of the uniform minor H antigen
typing methodology, 22 cell lines from the 13
th International
Histocompatibility Workshop Symposium (IHWS) reference panel
were typed. These cell lines are generally available and have been
used before by several researchers to identify novel minor H
antigens [10,38]. The results are depicted in Table 3. These data
may serve as standard quality controls for clinical and research
laboratories.
Minor H antigen database development and
applications
The minor H antigen database (dbMinor) supports 4 applications,
i.e. the minor H antigen database (I), the minor H antigen search
based upon HLA typing (II), a full donor/recipient minor H
antigen and HLA typing analysis (III), and a data submission
Table 2. Validation of the PCR-SSP minor H antigen typing methodology.
..................................................................................................................................................
EBV-LCL Original typing Original methodology Ref. PCR-SSP Typing
HAR03 HA-1
2/HA-1
HH CTL and sequencing [7,26] HA-1
HH
HAR05 HA-1
2/HA-1
RR CTL and sequencing HA-1
RR
HEL02 HA-2
+/HA-2
VM CTL and sequencing [6,27] HA-2
VM
HEL03 HA-2
2/HA-2
MM CTL and sequencing HA-2
MM
HoRe HA-3
+/HA-3
TT CTL and sequencing [12] HA-3
TT
HoDo HA-3
2/HA-3
MM CTL and sequencing HA-3
MM
SKH HA-8
+/HA-8
RP CTL and sequencing [9,43] HA-8
RP
SDK HA-8
2/HA-8
PP CTL and sequencing HA-8
PP
MT HB-1
HH PCR-RFLP H. Dolstra, personal communication HB-1
HH
HM HB-1
YY PCR-RFLP HB-1
YY
IHW1182 ACC-1
YY CTL/linkage [10] ACC-1
YY
IHW1018 ACC-1
CC CTL/linkage ACC-1
CC
IHW1182 ACC-2
DD CTL/linkage [10] ACC-2
DD
IHW1018 ACC-2
GG CTL/linkage ACC-2
GG
DRN SP110
+ CTL and PCR-RFLP [14] SP110
RG
CAN SP110
2 CTL and PCR-RFLP SP110
GG
KSN PANE1
RStop CTL and PCR-RFLP [13] PANE1
RStop
GAO PANE1
StopStop CTL and PCR-RFLP PANE1
StopStop
RAR UGT2B17
+ CTL and PCR [11] UGT2B17
+
DCR UGT2B17
2 CTL and PCR UGT2B17
2
MoDo H-Y
+ CTL [22] H-Y
+
ReRe H-Y
2 CTL H-Y
2
doi:10.1371/journal.pone.0000042.t002
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PLoS ONE | www.plosone.org 3 December 2006 | Issue 1 | e42section (IV). All 4 components of the database and the applications
are mutually linked (Figure 2).
I. The minor H antigen database The minor H antigen
database allows data searches for basic information on individual
minor H antigens. The information includes the references to the
relevant articles, the amino-acid sequence of the peptide, and the
HLA restriction molecule. If available, links show the related
clinical studies, the genes and the protein data available at the
NCBI. Likewise, detailed information on tissue distribution and
mRNA expression are included.
II. The minor H antigen search based upon HLA
typing This searching method has been designed to list the
Figure 1. Minor H antigen PCR-SSP. PCR-SSP of DNA of two unrelated individuals (CAN and 80821) was performed and analyzed as described in the
Materials and Methods section. The first lane of each minor H locus represents the immunogenic allele; the second lane displays the non-
immunogenic allele. Bands relevant for minor H antigen typing are boxed. The products of 439 and 504 bp reflect the internal control for the
immunogenic and the non-immunogenic allele respectively. The control band for UGT2B17 has a size of 761 bp. Since the minor H antigens UGT2B17
and H-Y have no allelic counterpart, the latter typing was performed with a single set of primers.
doi:10.1371/journal.pone.0000042.g001
Table 3. Minor H antigen genotyping of 11 parental CEPH cell lines from the 13
th IHIWS.
..................................................................................................................................................
HA-1 HA-2 HA-3 HA-8 HB-1 ACC-1 ACC-2 SP110 PANE1 UGT2B17 H-Y
IHW1003 HR VV MM RP HY CC GG RG R - + 2
IHW1010 HH VV MM RR HH CC GG RG R - ++
IHW1029 RR VV TM RP HY CC GG RR RR ++
IHW1031 RR VV TM RP HH CC GG RG RR + 2
IHW1045 HR VV TM PP HY CC GG RG R - + 2
IHW1046 RR VV TM RP HH YC DG GG R - ++
IHW1053 HR VV MM RR HH CC GG RR R - + 2
IHW1056 HH VV MM RR HH CC GG RG R - ++
IHW1074 RR MM TM RR HH CC GG RG RR + 2
IHW1077 HR VV TT RP HH CC GG RG R - 2 +
IHW1088 RR VM TT PP HH CC GG RR RR + 2
IHW1091 RR VV TT RP HH YC DG RG RR ++
IHW1103 RR VV TT RP HY CC GG GG R - ++
IHW1108 HR VV TT RP HH YY DD RG R - + 2
IHW1116 HR VV TM RP HH YC DG RG RR ++
IHW1117 HH VV TM PP HH CC GG RG R - + 2
IHW1124 HR VV TM RP HH CC GG RR R - ++
IHW1135 RR VM TM PP HH YC DG RR R - + 2
IHW1141 HR VV TM RP HH YC DG RG R - ++
IHW1143 HR VV TT PP HH CC GG RR R - 22
IHW1161 RR VV TT PP HH CC GG RG RR ++
IHW1166 HH VV MM RP HH CC GG RG RR + 2
Typing is depicted as the amino acid resulting from the genomic sequences. The stop codon for PANE1 is indicated by a ‘‘-‘‘.
doi:10.1371/journal.pone.0000042.t003
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Minor H Antigen Typing Tools
PLoS ONE | www.plosone.org 4 December 2006 | Issue 1 | e42potential expression of minor H antigens in an individual based
upon the individuals’ HLA typing. HLA typing has to be entered
in a two-digit format. The results of the query give an indication
whether minor H antigens may play a role in post-transplant
immune reactivity and for which minor H antigens typing should
be performed. In case HLA sub-alleles have been reported to be
unable to express the minor H antigen of interest, it is specifically
listed in the results.
III. Full donor/recipient minor H antigen and HLA typing
analysis The combined HLA and minor H antigens typing
results of the donor/recipient pair under study subsequently
provides information on putative minor H antigen reactivity. An
automatic query has been designed to analyze these putative
immune reactivities. Upon submission of the locally obtained
minor H antigen typing results in combination with the 2-digit
HLA typing data (Figure 3a) the algorithm filters all minor H
antigens for the HLA restriction molecules expressed in the
donor/recipient pair and provides the direction of the potential
immune reactivity per individual minor H antigen (Figure 3b). In
case the donor and recipient are matched for a relevant minor H
antigen, a ‘‘=’’ symbol appears. In case of mismatches, the
direction of the potential immune reactivity/reactivities is/are
indicated with an arrow from recipient to donor in the case
rejection and from donor to recipient in the case of GvHD/GvT
reactivity. Since a link is created to the tissue distribution of each
minor H antigen, clinically relevant information is subsequently
provided. If HLA sub-alleles have been reported to be unable to
express the minor H antigen of interest, this is specifically listed in
the results.
IV. Data submission section New minor H antigen data
can be submitted directly to the dbMinor (http://www.lumc.nl/
dbminor/submit.html). Submission of information includes local
minor H antigen designation, amino acid sequence of the peptide
of the immunogenic allele and, if relevant, its allelic counterpart,
the HLA restriction molecule, phenotype frequency of the minor
H antigen, name of the gene encoding the T cell epitope as
assigned by the HUGO Gene Nomenclature Committee, links to
Entrez Gene and Homologene, tissue distribution on the cellular
and/or RNA level. Optional data that can be submitted are:
reference(s) to relevant publications and to clinical studies. If
requested, peptide sequence data and protein/gene information
can be treated as confidential until publication. The submissions
will be generally screened on correctness and made public via the
database after final permission of the submitting author. The
responsibility of the accuracy of the submitted data remains with
the submitting author(s).
DISCUSSION
Routine typing for minor H antigens of stem cell and solid organ
transplant donor and recipient is a prerequisite for their potential
clinical use and provides insights in the minor H antigen allo-
immune reactivities [39]. A universal and simple methodology
enabling genomic minor H antigen typing was, as yet, non-
existing. We here describe a uniform protocol for the genomic
typing of the currently molecularly identified minor H antigens.
Our basic requirements for the development of the method were:
1) easy implementation in routine HLA typing laboratories, 2)
high reliability, and 3) optimal reproducibility. To further facilitate
implementation in routine HLA tissue typing, PCR primers were
designed to run on the most common temperature profile for HLA
typing [36]. Choosing separate temperature profiles for each
individual minor H antigen might increase the yield of the PCR
product. Particularly the PCR-SSP for HA-1 and HB-1 may
benefit from such an adaptation. This however also implicates that
screening of a single DNA sample would require different PCR
runs. Since the yield of HA-1 and HB-1 PCR products is
sufficiently high for reliable detection, a single methodology
approach is preferred over the optimal amplification. To check its
reproducibility, all experiments in this study were performed at
least twice, yielding identical results in all experiments (data not
shown). Subsequent typing of previously otherwise typed DNA
materials demonstrated perfect matching with earlier results
(Table 2). Once established, 22 parental CEPH reference cell
lines were minor H antigen typed with the developed methodology
(Table 3). These typing results can function as reference for the
laboratories implementing the minor H antigen typing method-
ology.
Today, information on minor H antigen typing may have
relevant spin-offs in the area of stem cell and renal transplantation.
Regarding the former, typing of donor/recipient pairs prior to
SCT provides information on two crucial GvH reactivities; i.e.;
GvHD and GvT. Broadly expressed minor H antigens are prone
to causing GvHD. Pre-SCT information on the disparities for the
broad minor H antigens is relevant enabling early anticipation on
putative development of GvHD. Minor H antigens with tissue
distribution restricted to the hematopoietic system play a role in
the graft-versus-leukemia (GvL) effect post-SCT [40]. Typical
examples of the latter group are: HA-1, HA-2, HB-1, ACC-1,
ACC-2, PANE1 and SP110 [8,10,13,14,32]. Disparities for these
minor H antigens in the GvH direction facilitate the GvL effects of
SCT. These GvL effects can be boosted by adoptive immuno-
therapy using hematopoietic system specific minor H peptides;
similarly in the case of SCT for solid tumors the GvT effect can be
boosted using minor H peptides expressed on the carcinoma cells
but absent on their healthy epithelial counterparts [40].
Beside the development of a uniform genomic typing method
for minor H antigens, quick and easy interpretation of the
potential clinical consequences of the minor H antigen typing
Figure 2. Structure of the minor H antigen database (dbMinor). Data
from dbMinor are obtained via direct submission and from literature
screening. The data in dbMinor can be analyzed via an HLA-based
query, a full typing query and a minor H antigen query. Results from
these queries are linked to external data from the NCBI database.
doi:10.1371/journal.pone.0000042.g002
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PLoS ONE | www.plosone.org 5 December 2006 | Issue 1 | e42Figure 3. Analysis of donor/recipient HLA and minor H antigen typing.
A. Query section: Minor H antigen typing data can be entered by marking the checkboxes per allele per minor H antigen. HLA typing data has the 2-
digit format. Full typing for all HLA loci is not required. After submitting the query, a page with results will appear
B. Results: The results section lists minor H antigens relevant in the particular donor-recipient combination based upon the HLA typing. In case donor
and recipient are minor H antigen matched, as is the case here for HA-1, the sign ‘‘=’’ will appear between donor and recipient. In case recipient and
donor are minor H antigen mismatched, the disparities are indicated by an arrow. The direction of the arrow indicates the direction of the immune
responses. In this example immune reactivity can occur in the recipient-to-donor (host-versus-graft, rejection) direction for HA-2 and HA-3 and in the
donor-to-recipient (graft-versus-host) direction for HA-8 and for the various H-Y antigens.
The tissue distribution of each relevant minor H antigen is listed as ‘‘broad’’ or ‘‘restricted’’. By clicking these terms, a detailed list of target cells
expressing the minor H antigen will be displayed.
Minor H antigens are presented by selected HLA molecules. The HLA alleles expressed by recipient and donor that are not able to present a minor H
antigen are listed at the bottom of the results section. Information will appear in case a particular minor H antigen cannot be presented by a specific
HLA sub-allele (4-digit format; in this example HLA- DQB1*0503/0504 for DQ5/H-Y).
doi:10.1371/journal.pone.0000042.g003
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PLoS ONE | www.plosone.org 6 December 2006 | Issue 1 | e42results are desired. Interpretation of the typing results in relation to
GvH reactivities in SCT is rather complex; the recipient requires
to be homozygous or heterozygous for the immunogenic minor H
allele, while the donor should be homozygous for the non-
immunogenic allele. Minor H antigens are peptides encoded by
polymorphic proteins. In general, only one polymorphic allele of
the protein is immunogenic. Some exceptions are reported, e.g.
the HLA-B44 restricted HB-1 and the HLA-B60 restricted HA-1
can be immunogenic bidirectionally [41,42]. Furthermore, minor
H antigens are presented in the context of a certain HLA allele.
Moreover, as discussed earlier, minor H antigens have different
and distinct tissue expression patterns resulting in differential GvH
reactivities. Thus, the complex combination of these various
characteristics hampers rapid interpretation of the minor H
antigen typing results. We therefore developed algorithms to
facilitate the analysis of the minor H antigen typing results. This
novel application supports in interpreting the typing data with
regard to putative minor H antigen specific allo-immune responses
and in selecting the correct minor H antigens for adoptive
immunotherapy in the relevant donor/recipient pairs.
In all algorithms implemented in dbMinor, the two-digit HLA
typing format is used instead of the high resolution 4-digit format.
The rationale behind this strategy is lack of complete data
regarding this issue for most minor H antigens. For some minor H
antigens sub-alleles have been reported that are unable to present
the minor H antigen of interest. For example the HLA-DQ5/H-Y
minor H antigen can be presented by individuals who carry either
the HLA-DQB1*0501 or the HLA-DQB1*0502 allele. However,
the HLA-DQB1*0503 and HLA-DQB1*0504 alleles are unable to
present this particular H-Y peptide (Laurin et al. in press). If such
exceptions have been reported, they are specifically listed. As soon
as more information on this issue becomes available for other
minor H antigens, 4-digit-based queries will be implemented.
In summary, we here describe a universally applicable genomic
PCR-based minor H antigen typing protocol. It offers a simple,
uniform, and rapid methodology to determine minor H antigen
genotypes of all currently molecularly identified minor H antigens.
The methodology can be combined with the online applications
for the interpretation of minor H antigen typing results identifying
donor/recipient pairs eligible for adoptive immunotherapy and
patients with increased risk for developing GvHD. The minor H
antigen genomic methodology combined with the online applica-
tions will further facilitate the clinical application of minor H
antigens in transplantation.
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